Physician profile
Gary L Worcester
NPI 1003810029
$2,888.54
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $412 · 2021: $362 · 2022: $575 · 2023: $560 · 2024: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $497.39 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $276.26 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $273.96 | 2019-2024 | Camzyos, Eliquis |
| Abbott Laboratories | $224.70 | 2019-2023 | Aveir, Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.62 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.55 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $168.14 | 2019-2024 | Farxiga |
| Shockwave Medical, INC | $143.98 | 2020 | |
| Amarin Pharma, INC. | $135.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $121.62 | 2019-2022 | |
| Heartflow, INC. | $118.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.25 | 2019-2024 | |
| Amgen INC. | $91.56 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $46.90 | 2023 | Onpattro |
| Esperion Therapeutics, INC. | $45.95 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $30.66 | 2021-2023 | Opsumit |
| Novo Nordisk INC | $23.40 | 2023 | Ozempic, Rybelsus |
| Althera Pharmaceuticals LLC | $20.57 | 2022 | |
| Kestra Medical Technology Services, INC. | $18.05 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.03 | 2023 | Arcalyst |
| Vifor Pharma, INC. | $16.46 | 2019 | |
| Recor Medical INC | $15.56 | 2024 | Paradise Renal Denervation System |
| Chiesi USA, INC. | $14.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.87 | 2019 | |
| Irhythm Technologies, INC. | $12.77 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.49 | 2021 | |
| Bardy Diagnostics, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Worcester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.